Document is current
Any future updates will be listed below
-
Authors
Atreja, Nipun
Dubey, Anandkumar
Kang, Amiee
Jiang, Jenny
Hagan, Melissa
Michael-Asalu, Abimbola
Cheng, Dong
Deitelzweig, Steven
- License Information
-
More Information
Article History
Received: 20 September 2024
Accepted: 17 December 2024
First Online: 30 January 2025
Declarations
:
: Anandkumar Dubey, Amiee Kang, Jenny Jiang, and Dong Cheng are employees of BMS and may hold stock options. Nipun Atreja and Melissa Hagan were employees of BMS when the study was conducted. Nipun Atreja is currently affiliated with Immunovant. Melissa Hagan is currently affiliated with BeiGene. Abimbola Michael-Asalu is an employee of STATinMED. Steven Deitelzweig received research and consulting support from Pfizer and BMS.
: Since this study did not involve the collection, use, or transmittal of individually identifiable data, Institutional Review Board (IRB) approval was not required. This study only analyzed de-identified data which are a priori exempt from the Federal Policy for the Protection of Human Subjects (1991) and do not meet the identification criteria necessary to be privileged under the Health Insurance Portability and Accountability Act (HIPAA). Both the data and the security of the offices where the data were kept met HIPAA requirements. All authors had permission to access and use the database utilized in this study.
